Invex Therapeutics (ASX:IXC) reported Friday a loss of AU$0.0047 per diluted share for the half year ended Dec. 31, 2024, compared with a loss of AU$0.0281 per diluted share a year earlier.
The company's attributable loss after tax narrowed 83% to AU$356,535 from AU$2.1 million in the year-ago period, the filing said.
The biopharmaceutical company did not declare a dividend during the reported period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。